Attovia Therapeutics, Inc.

Attovia Therapeutics NASDAQ: ATTO reported 12-week results from a small phase 1b study of its experimental itch treatment ATTO-1310, saying a single dose produced sustained responses in patients with chronic pruritus of unknown origin and in those with high-itch atopic dermatitis.

Results build on preliminary Week 4 findings, in which a single dose of ATTO-1310 demonstrated rapid, deep, and durable itch relief in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) The single dose also delivered skin lesion improvements that deepened through Week 12 in patients with high-itch AD Approximately 95% suppression of IL-31 through Week 12 supports potential for quarterly dosing Initiation of global Phase 2 trials of ATTO-1310 in patients with chronic pruritu…

SAN CARLOS, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences: Guggenheim 3 rd Annual Healthcare Innovation Conference Format: Fireside chatDate: Tuesday, November 10, 2026Time: 3:30 PM - 3:55 PM…

SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026.

Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences:

ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026

Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that could reshape your portfolio heading into a volatile fall.

Attovia Therapeutics (NASDAQ:ATTO) has arrived on public markets with a pipeline built entirely on one bet: that a biparatopic antibody platform called Attobody can turn well-validated immunology targets into next-generation biologics.

Attovia Therapeutics, Inc. (NASDAQ: ATTO - Get Free Report) Director Colin Walsh purchased 85,000 shares of the firm's stock in a transaction dated Wednesday, August 5th. The stock was bought at an average cost of $21.00 per share, for a total transaction of $1,785,000.00. Following the acquisition, the director directly owned 85,000 shares in the company,

Attovia Therapeutics, Inc. (NASDAQ: ATTO - Get Free Report) major shareholder Global Strategic Fund Venbio purchased 382,352 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The shares were purchased at an average cost of $17.00 per share, with a total value of $6,499,984.00. Following the completion of the acquisition, the

Attovia Therapeutics, Inc. (NASDAQ: ATTO - Get Free Report) major shareholder Redmile Group, Llc bought 200,000 shares of Attovia Therapeutics stock in a transaction on Thursday, August 6th. The shares were acquired at an average cost of $17.00 per share, with a total value of $3,400,000.00. Following the completion of the acquisition, the insider owned 982,854